Female Sexual Dysfunction Guidance Should Be Revised, Intrinsa Cmte. Says

FDA should consider revising the recommended primary endpoint for female sexual dysfunction clinical trials, members of the Reproductive Health Drugs Advisory Committee said Dec. 2